The cancer-causing form of the gene Myc alters the metabolism of mitochondria, the cell's powerhouse, making it dependent on the amino acid glutamine for survival. In fact, 40 percent of all "hard-to-treat" cancers have a mutation in the Myc gene.
Accordingly, depriving cells of glutamine selectively induces programmed cell death in cells overexpressing mutant Myc.
Using Myc-active neuroblastoma cancer cells, a team led by Howard Hughes Medical Institute (HHMI) investigator M. Celeste Simon, Ph.D., scientific director for the Abramson Family Cancer Research Institute (AFCRI), identified the proteins PUMA, NOXA, and TRB3 as executors of the glutamine-starved cells. These three proteins represent a downstream target in the Myc pathway at which to aim drugs. Roughly 25 percent of all neuroblastoma cases are associated with Myc-active cells.
The findings appear in this week's issue of Cancer Cell. Simon is also a professor of Cell and Developmental Biology at the Perelman School of Medicine, University of Pennsylvania. The Penn team collaborated with colleagues from The Children's Hospital of Philadelphia (CHOP) John Maris and Michael Hogarty.
"These findings come from studies of fundamental cellular pathways and would not have been discovered without ongoing support for basic research," notes Simon. "Translational research is very important, but equal emphasis on basic research of processes such as cellular metabolism is critical for the ultimate cure of cancer."
Glutamine depletion in Myc-mutant cells induces cell death through a complicated series of molecular switches involving the three protein executors and the DNA-binding protein ATF4. Knowing this, the team showed that either agonists of ATF4 or inhibitors of glutamine metabolism potently caused cell death in assays using neuroblastoma cells and inhibited tumor growth in transgenic mice. Drugs in these two classes have been approved by the Food and Drug Administration and are being tested in clinical trials for other disorders.
University of Pennsylvania School of Medicine: http://www.uphs.upenn.edu/news/
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Cancer-fighting drug romidepsin has been shown to expose hibernating HIV, making it susceptible to attack
Oversleep causes a feeling similar to feeling hung over and it's caused by the same biological function that gives you jet lag.
Early results of a drug combination called PaMZ offer the best hope in decades of bringing the pernicious, drug-resistant form of tuberculosis under control
The U.S. Centers for Disease Control and Prevention "may never know" how a fairly harmless form of bird flu was cross-contaminated with a dangerous bird flu strain before it was sent to a laboratory outside of the CDC, an agency spokesman said on Monday.
A group of seven leading drugmakers has agreed to share an array of neglected experimental medicines with British academic researchers in the latest example of the deepening ties between industry and external scientists.
As a part of TV experiment, a sidewalk in the nation's capital seperates those who wish to walk and text from those who don't
Warning over growing resistance to antiretrovirals dampens hopes that Aids can be eliminated by 2030
Dozens of passengers on the Malaysia Airlines plane were thought to have been heading to a major international Aids conference in Australia.
Australian scientists starve parasite of crucial proteins, providing a target for the development of new antimalarials
Heading off to exotic locales to conduct research is one of the great joys of science. But many young scientists say they have been sexually harassed or assaulted by superiors while out there.